No Data
No Data
Obu Biology (300357.SZ): Currently, the stem cell drug being developed by the company's subsidiary is in the preclinical research stage, and it is impossible to predict the time of industrialization
Gelonghui, May 10 | Our Wu Biology (300357.SZ) said on the investor interactive platform that the indications for stem cell drug research projects can be reviewed in advance. Furthermore, innovative drug development has the characteristics of long cycle, large investment, and high uncertainty. Currently, stem cell drugs being developed by the company's subsidiaries are in the preclinical research stage, and it is impossible to predict the time for industrialization.
Waku Biotech (300357.SZ): Does not involve diabetes-related indications
Gelonghui, May 9丨Our Wu Biology (300357.SZ) said on the investor interactive platform that the company's subsidiary's stem cell drug research project is currently in the preclinical research stage and does not involve diabetes-related indications.
Are Investors Undervaluing Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357) By 24%?
Key Insights Zhejiang Wolwo Bio-Pharmaceutical's estimated fair value is CN¥30.47 based on 2 Stage Free Cash Flow to Equity Zhejiang Wolwo Bio-Pharmaceutical is estimated to be 24% undervalued based
Wowu Biotech (300357.SZ): Net profit of 310 million yuan in 2023, plans to distribute 10 to 1.85 yuan
Gelonghui, April 18 | WuWu Biotech (300357.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 848 million yuan, a year-on-year decrease of 5.34%; net profit attributable to shareholders of listed companies was 310 million yuan, a year-on-year decrease of 11.06%; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 298 million yuan, a year-on-year decrease of 5.20%; basic earnings per share were 0.5924 yuan; it plans to distribute a cash dividend of 1.85 yuan (tax included) to all shareholders for every 10 shares.
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s (SZSE:300357) Stock Price Dropped 5.6% Last Week; Private Companies Would Not Be Happy
Key Insights Zhejiang Wolwo Bio-Pharmaceutical's significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 3 investors
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s (SZSE:300357) 29% Price Boost Is Out Of Tune With Earnings
Those holding Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357) shares would be relieved that the share price has rebounded 29% in the last thirty days, but it needs to keep going to repair th
No Data